Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
BreezeBio logo — Genetic Medicine Delivered

BreezeBio

Genetic Medicine Delivered

Founded 2016 United States Brisbane, United States 64 employees Series B Total: $118.50M Biotechnology

General Information

Company Name BreezeBio
Founded Year 2016
Location United States Brisbane, United States
Employees 64
Industries Biotechnology
Funding Stage Series B
Business Model B2B, Platform, B2B2C
Revenue Model Licensing, Performance Based, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with BreezeBio. To contact BreezeBio, visit breezebio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BreezeBio compare?

A PDF of BreezeBio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BreezeBio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BreezeBio

BreezeBio, with the slogan "Genetic Medicine Delivered," is a biotechnology company focused on creating precision genetic medicines. Established in 2016 and situated in the South San Francisco area, the company specializes in non-viral delivery methods for genetic therapies across biologically relevant tissues.

Their proprietary NanoGalaxy® platform is engineered to deliver genetic payloads, like mRNA, to specific cell types. This platform has shown effective delivery to immune cells and several tissues in the heart, lung, and central nervous system. BreezeBio is progressing its internal therapeutic pipeline, targeting autoimmune diseases and oncology, with its flagship program, BRZ-101, advancing towards IND-enabling studies in type 1 diabetes.

Recently, the company secured a $60.00M Series B investment, underscoring investor confidence in its innovative approach and growth potential in the genetic medicine space.

Business keywords: Precision Medicine, Genetic Medicine, Non-Viral Delivery, NanoGalaxy® Platform, Nanoparticles, mRNA Delivery, Immune Cells, Tissue Specific Delivery, Autoimmune Diseases, Oncology, Type 1 Diabetes, Immune Tolerance, Therapeutic Pipeline, IND-Enabling Studies

Services & Products

Targeted delivery of genetic medicines
Development of immune modulation therapies
Research and development of precision genetic medicine platforms

Target Customers

Healthcare professionals Biopharmaceutical companies Patients with autoimmune diseases Research institutions

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $60.00M -
01 Feb 2026
Series A $24.00M 18
Korea Investment Partners KB Investments Korea Development Bank
Korea Investment Partners, KB Investments +16
01 Jan 2024
Series A $26.00M 12
DCVC Korea Investment Partners Company K Partners
DCVC, Korea Investment Partners +10
01 Sep 2021
Seed $8.50M 4
DCVC Bow Capital SK Group
DCVC, Bow Capital +2
01 Dec 2018
Spinout Undisclosed 1
University of California, Berkeley
01 Dec 2016
Seed Undisclosed 2
Bow Capital
Bow Capital, Sequoia
01 Aug 2016

BreezeBio Alternatives & Competitors

View All Alternatives
BreezeBio vs
GenEdit
GenEdit United States

Delivering the potential of genetic medicines

Series A
47 employees
Biotechnology, Health and Wellness
Compare BreezeBio vs GenEdit
BreezeBio vs
Hopewell Therapeutics, Inc.
Hopewell Therapeutics, Inc. United States

Enabling a new generation of genomic medicines for patients with high unmet medical needs.

Seed
13 employees
Biotechnology, Health Care
BreezeBio vs
Gennao Bio
Gennao Bio United States

A genetic medicines company developing first-in-class, targeted nucleic acid therapeutics

Series A
5 employees
Biotechnology, Health Care
View all alternatives

FAQ About BreezeBio

Genetic Medicine Delivered
BreezeBio was founded in 2016.
BreezeBio is headquartered in Brisbane, United States.
BreezeBio operates in Biotechnology. Its work centres on Precision Medicine, Genetic Medicine, Non-Viral Delivery and NanoGalaxy® Platform. Its customers include Healthcare professionals, Biopharmaceutical companies and Patients with autoimmune diseases.
BreezeBio has a B2B, Platform and B2B2C business model. Its revenue comes from Licensing, Performance Based and Product Sales.
BreezeBio has approximately 64 employees.
BreezeBio has completed 6 funding rounds, raising a total of $118.50M. The latest funding stage is Series B.
BreezeBio offers: Targeted delivery of genetic medicines, Development of immune modulation therapies, Research and development of precision genetic medicine platforms.
Top alternatives and competitors to BreezeBio include GenEdit, Hopewell Therapeutics, Inc., Gennao Bio, ReCode Therapeutics, Beam Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BreezeBio and GenEdit are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BreezeBio, https://bouncewatch.com/company/breezebio, updated 29 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes